Replimune (REPL) shares climbed more than 60% in the premarket on Friday after the company announced plans to resubmit a marketing application for its lead asset RP1 in the U.S., following its second ...

Replimune Group, Inc.'s RP1 has failed at the FDA twice, but Makary's resignation keeps a resubmission possible. REPL's cash runway stands at under a year; workforce cuts and RP1 discontinuation are ...

Shares of Replimune Group, Inc. (REPL Quick Quote REPL - Free Report) have gained 2.7% over the past four weeks to close the last trading session at $7.16, but there could still be a solid upside left ...

Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

bug good first issueA simple tasks suitable for first-time contributorsA simple tasks suitable for first-time contributors Sometimes when I'm on a ClojureScript buffer, I want to trigger a project ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Infrastructure consultants Rudrabhishek Enterprises Ltd (REPL) has announced that it has received approval for the Securities and Exchange Board of India (SEBI) to register a small and medium real ...

Saudi Arabia - Al Ojaimi Industrial Group, a pioneer in the electrical manufacturing sector, has entered into a new joint venture with REPL International, the REPL Industry Company factory in Riyadh, ...

I've been programming in Clojure as a fullstack engineer and I think CLJC is the way. A refresher: if you give a Clojure code file .cljc extension it will be compiled by both ClojureScript and Clojure ...

Replimune (NASDAQ:REPL) stock is falling hard on Tuesday after the clinical-stage biotechnology company shared a primary analysis of its CERPASS trial. This trial is evaluating RP1 alongside ...